Fig. 2.
Analysis of PFS in patients with bcl-2 and tumor proliferation (MIB-1) markers.
(A) PFS rates in 29 patients divided into bcl-2–negative (*) and bcl-2–positive groups (○) were 82% and 50%, respectively, at 62 months (P2 = .036 overall). (B) PFS rates in 33 patients divided into MIB-1 of 80% or greater (○) and less than 80% (*) were 74% and 62%, respectively, at 62 months (P2 = .24 overall).
